| Course | NU648 Specialized Pharmacology for the AGACNP |
|---|---|
| Unit | Unit 5 |
| Paper type | Seminar reflection |
| Length | About 860 words, 6 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | MSN |
| Updated | September 2026 |
Free sample paper for NU648 Unit 5
The Antidote or the Concentrate: A Seminar Reflection on Reversing Apixaban After a Brain Bleed
[Student Name]
Purdue University Global
NU648: Specialized Pharmacology for the AGACNP
Unit 5 Seminar Reflection
[Instructor Name]
[Date]
The seminar case is composite; times, volumes and scores are bracketed, and the classmate who challenged my position is not named.
The Case We Discussed
The seminar case was a [78]-year-old man who fell at home and arrived [four] hours later with a headache and mild right-sided weakness. His last apixaban dose, [5 mg], was taken [six] hours before arrival for atrial fibrillation. CT showed a left thalamic hemorrhage of about [14] mL with no intraventricular extension. His Glasgow Coma Scale score was [14] and his NIH Stroke Scale score was [6]. The detail that later changed my answer was in his history: an ischemic stroke [eight] months earlier, which was the reason he had been started on apixaban.
The facilitator asked us to choose a reversal strategy and defend it in two minutes.
Where I Started
I argued for andexanet alfa. My reasoning was that it is the specific reversal agent for factor Xa inhibitors, designed to bind the drug, while prothrombin complex concentrate works around the drug by adding clotting factors. I cited the 2022 American Heart Association and American Stroke Association guideline, which rates andexanet as reasonable for factor Xa inhibitor associated hemorrhage and gives prothrombin complex concentrate a weaker recommendation (Greenberg et al., 2022). I also pointed to the 2020 ACC decision pathway, which lists andexanet first for life-threatening bleeding on apixaban or rivaroxaban and prothrombin complex concentrate when andexanet is not available (Tomaselli et al., 2020).
I still think that opening was reasonable. Both documents supported it at the time they were written, and a specific antidote has an obvious appeal when a hematoma may be growing.
The Challenge
A classmate asked a question I had not prepared for: what did ANNEXA-I show about strokes, and does this man's history change the answer? I knew the trial name but not the safety results, and I said so.
After the seminar I read the trial. ANNEXA-I randomized 530 patients with intracerebral hemorrhage who had taken a factor Xa inhibitor within 15 hours to andexanet or usual care, and 85.5 percent of the usual care group received prothrombin complex concentrate (Connolly et al., 2024). Hemostatic efficacy, a composite of limited hematoma growth, no major neurologic worsening and no rescue therapy, was achieved in 67.0 percent with andexanet and 53.1 percent with usual care. That supported my opening position. But thrombotic events occurred in 10.3 percent with andexanet and 5.6 percent with usual care, and ischemic stroke in 6.5 percent against 1.5 percent. There was no clear difference in function on the modified Rankin scale or in death at 30 days.
The trial answered the question I had asked, whether andexanet controls bleeding better, and raised the question my classmate asked, whether that control costs clots.
What Changed and Why
Two things changed my answer for this patient. The first was the size of the thrombotic signal compared with the absence of a functional benefit. A better scan at 12 hours matters only if it becomes a better life at 30 days or later, and the trial did not show that. The second was his history. A man whose ischemic stroke is eight months old is exactly the patient in whom a fourfold difference in ischemic stroke would weigh most, even though the trial was not designed to test that subgroup.
His hematoma was also small, his examination was relatively mild and he arrived well inside the window. Those facts cut both ways. A small, early bleed has room to grow, which argues for the more effective hemostatic agent. It is also a bleed in which the absolute benefit of slightly less growth may be modest.
My revised position was four-factor prothrombin complex concentrate for this man, with repeat CT at [six] hours and a plan to discuss restarting anticoagulation with neurology once the hematoma was stable. I would still consider andexanet for a patient with a larger, expanding hemorrhage and no recent thrombotic event, where hematoma growth is the more immediate threat.
What I Would Do Differently
I learned more from being unable to answer the question than from the answer I gave. My preparation stopped at the guidelines, and both were written before ANNEXA-I was published. When a guideline predates the trial that tests its recommendation, I now read the trial before I cite the guideline. I also want to ask a different first question of any reversal decision: what does this patient's clot risk look like, not only how fast is he bleeding.
The next time a reversal case comes up, I plan to check three things before the seminar: the date of the guideline against the date of the largest trial, the absolute rates of benefit and harm rather than the relative ones, and the one feature of the patient that would make the harm matter most. For this man, that feature was a stroke eight months ago, and it was in the case summary from the start.
References
Connolly, S. J., Sharma, M., Cohen, A. T., Demchuk, A. M., Członkowska, A., Lindgren, A. G., Molina, C. A., Bereczki, D., Toni, D., Seiffge, D. J., Tanne, D., Sandset, E. C., Tsivgoulis, G., Christensen, H., Beyer-Westendorf, J., Coutinho, J. M., Crowther, M., Verhamme, P., Amarenco, P., . . . Shoamanesh, A. (2024). Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. New England Journal of Medicine, 390(19), 1745-1755. https://doi.org/10.1056/NEJMoa2313040
Greenberg, S. M., Ziai, W. C., Cordonnier, C., Dowlatshahi, D., Francis, B., Goldstein, J. N., Hemphill, J. C., III, Johnson, R., Keigher, K. M., Mack, W. J., Mocco, J., Newton, E. J., Ruff, I. M., Sansing, L. H., Schulman, S., Selim, M. H., Sheth, K. N., Sprigg, N., & Sunnerhagen, K. S. (2022). 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: A guideline from the American Heart Association/American Stroke Association. Stroke, 53(7), e282-e361. https://doi.org/10.1161/STR.0000000000000407
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., Messé, S. R., Perino, A. C., Rodriguez, F., Sarode, R., Siegal, D. M., & Wiggins, B. S. (2020). 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. Journal of the American College of Cardiology, 76(5), 594-622. https://doi.org/10.1016/j.jacc.2020.04.053
Reading the NU 648 Unit 5 instructions
The Unit 5 seminar reflection asks you to look back on a live discussion of a pharmacology decision and explain how your thinking developed. You summarize the case, state the position you brought to the seminar, describe the challenge or new information that tested it, weigh the evidence and state where you ended up and why. A reflection is written in the first person, but it is still graded on reasoning and sources. Most sections set 750 to 1,000 words with at least two scholarly references. The movement matters more than the final answer: a reflection that ends where it began, without testing anything, usually earns fewer points.
How this NU648 Unit 5 example is built
The example opens with the case in numbers, including the time since the last apixaban dose, the hematoma volume and the stroke scale score, and saves one detail for later: an ischemic stroke eight months earlier. The next section gives the opening argument fairly and credits it with what it had right. The challenge is reported in the classmate's words, unnamed, before any response. The ANNEXA-I results follow with absolute rates for hemostasis, thrombotic events and ischemic stroke. A section on what changed names two reasons, and the closing section turns the lesson into three checks the writer will run before the next reversal case.
Reading the NU648 Unit 5 grading rubric
The Unit 5 rubric weighs reflection on learning, integration of evidence, application to the case and the quality of the writing. Reflection earns full points when the change in thinking is specific: what you believed, what tested it and what you believe now. Evidence is judged on accuracy, so absolute rates from a trial count for more than a phrase such as better outcomes. Application rewards tying the evidence back to this patient, here his prior stroke, rather than to patients in general. Writing counts for organization and APA format. A revised position that states the conditions under which it would change back shows the kind of judgment the course is building.
Common NU648 Unit 5 mistakes, and how to avoid them
Reflections often narrate the seminar without reflecting on it, listing who said what without explaining what it changed. Another common mistake is citing a guideline without checking whether a newer trial has tested its recommendation, the exact gap this sample admits. Students sometimes present the revised answer as the only correct one; the stronger move is to name the patients for whom the original choice still fits. Some reflections leave out numbers because they feel too technical for a personal piece, but the grader wants the evidence. Finally, avoid naming the classmate who challenged you, since the discussion belongs to the group. Keep the case summary short, too. The reflection is about your reasoning, so a long retelling of the patient's history crowds out the part that earns points.
Get an NU648 Unit 5 example written to your instructions
Whichever two agents your NU648 Unit 5 seminar compared, share them with any posted case and the reflection prompt or written-alternative instructions. Free for a first order, the sample normally reaches you inside 24-48h and tracks how the comparison moved between two drugs, crediting the opening position with whatever it got right. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU648 papers and MSN samples
- NU648 Unit 1: Hypoglycemia Medication Review Post
- NU648 Unit 2: Dosing Weight Worksheet
- NU648 Unit 3: Adverse Drug Event Analysis
- NU648 Unit 4: Perioperative Medication Plan
- NU648 Unit 6: Multimodal Pain Plan on Buprenorphine
- NU648 Unit 7: QT Prolongation Risk Review
- NU648 Unit 8: Beers Criteria Prescribing Review
- NU648 Unit 9: Electrolyte Replacement Case
- NU648 Unit 10: Fidaxomicin vs Vancomycin Comparison
- NU610 Unit 5: Seminar Reflection
- NU605 Unit 5: Seminar Reflection
- NU603 Unit 5: Seminar Reflection
- NU590 Unit 5: Seminar Reflection
NU648 Unit 5 questions, answered
What if the seminar compared two agents I had not studied yet?
The reflection can say so; admitting a starting point of limited knowledge is honest and gives the movement somewhere to begin. The sample builds the comparison from the case and the primary sources named in the session, so a reader sees what was learned in the hour as well as what was concluded.
How much of the guideline should the reflection quote?
Very little. A reflection is judged on reasoning, so a sentence stating the recommendation, its strength and its year is usually enough. The sample quotes only the words the argument turns on, cites the full guideline, and gives the remaining space to what the recommendation means for this particular patient.
Can the reflection disagree with the instructor's view?
Yes, if the disagreement is argued from evidence and stated respectfully. Seminar reflections reward reasoning more than agreement. The sample shows a view changing because of evidence presented in the session; a reflection that holds a position against a challenge can be equally strong when it engages that challenge seriously.
Where can I find a free NU648 Unit 5 sample paper?
This page holds the complete NU648 Unit 5 seminar reflection on andexanet and prothrombin complex concentrate, with the case, the opening position, the challenge and the revised choice. For a seminar on another drug decision, you can request a free sample written around your topic.
Is andexanet or PCC preferred in NU648 Unit 5?
The sample does not name one answer for every patient. ANNEXA-I found better hemostatic efficacy with andexanet but more thrombotic events and ischemic strokes, with no clear functional benefit, so the reflection chooses prothrombin complex concentrate for a man with a recent stroke and keeps andexanet in view for others.